Concepedia

Adam J. Camblin

AJ

Statistics

Publications

5

Citations

259

H-Index

5

Active since

2018

Affiliations

Merrimack Pharmaceuticals (United States)(Current)

Beam Therapeutics (United States)

Massachusetts General Hospital

Adam J. Camblin is an author at Merrimack Pharmaceuticals (United States) specializing in crispr, cell transplantation, and gene expression.

Top concepts

Publications per year

2018–2024

5

Publications

5

Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL

Caroline Diorio, Ryan Murray, Mark Naniong et al. · Blood · 2022 · 119 citations · Full text

, , +28

Antibody-mediated targeting of TNFR2 activates CD8 <sup>+</sup> T cells in mice and promotes antitumor immunity

Eric M. Tam, Ross B. Fulton, James F. Sampson et al. · Science Translational Medicine · 2019 · 56 citations · Full text

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Adam J. Camblin, Emily A. Pace, Sharlene Adams et al. · Clinical Cancer Research · 2018 · 53 citations

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer

Adam J. Camblin, Gege Tan, Michael D. Curley et al. · Scientific Reports · 2019 · 21 citations · Full text

Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells

Colby R. Maldini, Angelica Messana, Paula B. Bendet et al. · Molecular Therapy · 2024 · 10 citations · Full text

Rows per page

1–5 of 5